Publications
- Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 20032015 | Second Faculty of Medicine
- Inhibitor development in non-severe haemophilia across Europe2015 | Second Faculty of Medicine
- Introduction of the treatment with recombinant FVIII has not increased the inhibitor incidence rate in Czech PUPs with haemophilia A2014 | Second Faculty of Medicine
- Severe congenital bleeding disorders manifesting in the neonatal period - case reports2022 | Second Faculty of Medicine
- Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for the diagnosis and treatment of patients with haemophilia, 3rd edition, year 20212021 | Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for the diagnosis and treatment of patients with congenital haemophilia and FVIII/ FIX inhibitors2021 | Second Faculty of Medicine, Faculty of Medicine in Pilsen
- A practical, one-clinic visit protocol for pharmacokinetic profile generation with the ADVATE(R) myPKFiT(R) dosing tool in severe hemophilia A subjects2021 | Second Faculty of Medicine
- octanate (R): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment2020 | Second Faculty of Medicine
- Intracranial haemorrhage in patients with haemophilia A2019 | Second Faculty of Medicine
- New era of management of patients with haemophilia - replacement therapy with coagulation factors VIII and IX with an extended half-life (EHL)2019 | Second Faculty of Medicine
Loading network view...